

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**  
**(Case No. 01-1693-N)**

In the Application of:

Fang, et al.

Serial No.: 09/896,874

Filed: June 29, 2001

For:    Compounds to Treat Alzheimer's Disease

Art Unit: 1621

Examiner: S. Kumar

## TRANSMITTAL LETTER


Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In regard to the above identified application,

1. We are transmitting herewith the attached:
  - a) Amendment Under 37 C.F.R. §1.312; and
  - b) Return Receipt Postcard.
2. With respect to fees:
  - a) No fee is due.
  - b) Please charge any underpayment or credit any overpayment our Deposit Account, No. 13-2490.
3. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on April 1, 2004.

Respectfully submitted,

  
Bradley W. Crawford  
Registration No. 50,494

CERTIFICATE OF MAILING

I hereby certify that this paper and every  
paper referred to therein as being enclosed  
is being deposited with the U.S. Postal Ser-  
vice as first class mail, postage prepaid,  
in an envelope addressed to: Commissioner  
for Patents, Alexandria, Virginia 22313,  
on April 1, 2004 (Date of Deposit)

4/1/04  
Date

Monica Eubanks  
Name

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Case No. 01-1693-N

In re Application of:

Fang, et al.

Serial No.: 09/896,874

Filed: 06/29/2001

For: Compounds for the Treatment  
of Alzheimer's Disease

Before the Examiner:  
Shailendra Kumar

Art Unit: 1621

Amendment Under 37 C.F.R. §1.312

Commissioner for Patents  
Arlington, VA 22313-1450

Dear Sir:

Responsive to the Notice of Allowability mailed March 15,  
2004, Applicants respectfully request the Examiner to reconsider  
the above-identified patent application in view of the following  
Amendments and Remarks.

The Listing of Claims begins on page 2 of this paper.  
Remarks begin on page 25 of this paper.

